

Immunohistochemical expression of fibronectin by stromal and epithelial cells in carcinoma of the female breast

Thesis

**Submitted for partial fulfillment of
MSc. degree in Pathology**

Submitted by

Passant Essam El Din Ahmed

M.B, B.CH; Cairo University

Supervised by:

Prof. Dr. Fahima Mohamed Habib

Professor of Pathology

Faculty of Medicine

Cairo University

Assistant. Prof. Mohammed Faisal Darweesh

Assistant Professor of Pathology

Faculty of Medicine

Cairo University

Dr. Lubna Omar El Farouk Abdel Salam

Lecturer of Pathology

Faculty of Medicine

Cairo University

2015

ACKNOWLEDGMENT

My foremost and greatest thankfulness to Allah.

I would like to express my sincere gratitude to ***Prof. Dr. Fahima Mohamed Habib***, Professor of Pathology, Faculty of medicine, Cairo University, for her close supervision, guidance, encouragement, precious remarks and great effort.

I am very grateful to ***Prof. Dr. Mohammed Faisal Darweesh***, Assistant Professor of Pathology, Faculty of medicine, Cairo University who devoted a great deal of his time to provide me with his kind guidance and valuable advices.

I would like to sincerely thank ***Dr. Lubna Omar El-farouk Abdel Salam***, Lecturer of Pathology, Faculty of Medicine, Cairo University for her friendly attitude and encouragement. She saved no time and effort in helping me and providing me with precious remarks.

All the respect and appreciation to ***Prof. Dr. Abdallah Mahmoud Khalil***, Professor and previous head of Pathology department, Faculty of medicine, Cairo University, for his unlimited support and valuable advices throughout this work.

Many thanks to my professors and colleagues who contributed to this work, whether with technical assistance, an advice, an idea, a book or even single word of encouragement.

No words can express my gratitude to my precious kind mother and dear sister, without their motivation, support and encouragement, this work would have never seen light.

Finally, I would like to dedicate this work with all love to the soul of my dear father, may his soul rest in peace

CONTENTS

Item	Page
Abstract	1
Introduction	2
Aim of work	4
Review of literature	
I. Epidemiology	5
II. Etiology and risk factors	7
III. Pathogenesis	24
IV. Classification	32
V. Staging	51
VI. Prognostic factors	54
VII. Epithelial mesenchymal transition	62
VIII. Tumor microenviroment	75
IX. Fibronectin	80
Materials & Methods	84
Results	87
Figures	129
Discussion	146
Summary	159
Conclusions & Recommendations	161
References	163
Arabic summary	

LIST OF ABBREVIATIONS

ACC	Acinic cell carcinoma
ADH	Atypical ductal hyperplasia
AIs	Aromatase inhibitors
AJCC	American Joint Committee on Cancer
AKT	Serine/threonine kinase
ALDH1	Aldehyde dehydrogenase
ALH	Atypical lobular hyperplasia
AMC	Atypical medullary carcinomas
AR	Androgen receptor
ATM	Ataxia Telangiectasia mutant gene
BBD	Benign breast diseases
BC	Breast cancer
BCL2	B-cell Lymphoma-2
BM	Basement membrane
BMI	Body mass index
BRCA	Breast cancer gene
BTICs	Breast tumor initiating cancer cells
CAFs	Cancer associated fibroblasts
CBC	Contralateral breast cancer
CBS	Conservative breast surgery
CCL7	Chemokine ligand 7
CDH1	Epithelial cadherin
CHEK2	Check point kinase 2
CK	Cytokeratin
COX2	Cyclo-oxygenase 2
CSC	Cancer stem cells
CXCL12	Chemokine ligand 12
DAB	Diaminobenzidine
DCIS	Ductal carcinoma insitu

DFS	Disease free survival
DM	Diabetes mellitus
DNA	Deoxyribonucleic Acid
DTCs	Disseminated tumor cells
E-cadherin	Epithelial-cadherin
ECM	Extracellular matrix
EDA, EDB	Extra domain-A, Extra domain-B
E-FN	Epithelial fibronectin
EGFR	Epidermal growth factor receptor
EMA	Epithelial membrane antigen
EMT	Epithelial-mesenchymal transition
ER	Estrogen receptor
ERK 1/2	Extracellular signal-regulated kinase 1/2
EU	European Union
FAK	Focal adhesion kinase
FEA	Flat epithelial atypia
FGF	Fibroblast growth factor
FLSpCC	Fibromatosis-like spindle-cell metaplastic carcinoma
FN	Fibronectin
FOX	Forkhead box
GCDFP- 15	15-kDa Glycoprotein of cystic breast disease
GSC	Homeobox protein goosecoid
GSK-3b	Glycogen synthase kinase-3b
GTPase	Guanosine triphosphatase
H/E (Spl)	Hairy and enhancer of split
HCG	Human Chorionic Gonadotropin
HER2	Human Epidermal growth factor receptor 2
HGF	Hepatocyte growth factor
HIF1α	hypoxia-inducible factor-1 α
HPF	High Power field

HRT	Hormone replacement therapy
IBC	Inflammatory breast cancer
IBIS	International breast cancer intervention
ICC	Invasive cribriform carcinoma
IDC-NOS	Invasive ductal carcinomas not otherwise specified
IDC-NST	Invasive ductal carcinomas no special type
IGF-1	Insulin-like growth factor-I
IHC	Immunohistochemistry
IL	Interleukin
ILC	Invasive lobular carcinoma
ILK	Integrin-linked kinase
IMPC	Invasive micropapillary carcinoma
IS	Immunoreactivity score
ITGA6	Alpha 6 integrin gene
JAK	Janus kinase
L.N.s	Lymph nodes
LCIS	Lobular carcinoma insitu
LGAS	Low-grade adeno-squamous carcinoma
LN	Lobular neoplasia
LNR	Lymph node ratio
LOXs	Lysyl oxidases
LTBP-1	Latent Transforming Growth Factor- β binding protein-1
LVI	Lymphovascular invasion
MAPK	Mitogen-associated protein kinase
MBC	Metaplastic breast carcinomas
MC	Medullary carcinoma
MD	Mammographic density
MEC	Mucoepidermoid carcinoma
MET	Mesenchymal–epithelial transition
MIC	Mononuclear inflammatory cell
MMP	Matrix metalloproteinases

MRI	Magnetic resonance imaging
MRM	Modified radical mastectomy
MSCs	Mesenchymal stem cells
nBSCs	Normal breast stem cells
N-cadherin	Neural cadherin
NE	Neuroendocrine
nF-κB	Nuclear factor-kb
NGS	Nottingham Grading System
NPD	Non-proliferative disease
OC	Oncocytic carcinoma
OCPs	Oral contraceptive pills
OGCs	Osteoclast-like stromal giant cells
OS	Overall survival
PALB2	Partner and localizer of BRCA2
PAS	Periodic acid–Schiff
PD	Proliferative disease
PDGF	Platelet-derived growth factor
PI3K	Phosphatidylinositol-3-kinase
PLCIS	Pleomorphic lobular carcinoma insitu
PR	Progesterone receptor
PRL	Prolactin
PTEN	Phosphate and tensin homology
RhoA	Ras homolog gene family
RNA	Ribonucleic acid
RTKs	Receptor tyrosine kinases
RT-PCR	Reverse Transcription–Polymerase Chain Reaction
SC	Sebaceous carcinoma
SCBC	Spindle cell breast carcinoma
SCC	Squamous cell carcinoma
SD	Standard deviation

SERMs	Selective estrogen receptor modulators
S-FN	Stromal Fibronectin
SHBG	Sex hormone binding globin
SPSS	Statistical Package for the Social Science
SRCC	Signet ring cell carcinoma
STAT3	Signal transducer and activator of transcription 3
TAMs	Tumor-associated macrophages
TC	Tubular carcinoma
TCF3	Transcription Factor 3
TGF-β	Transforming growth factor- β family
TLR	Toll-like receptor
TN	Triple Negative
TNF- α	Tumor necrosis factor- α
TNM	Tumor – Nodes - Metastasis.
TP53	Tumor protein 53
UDH	Usual ductal hyperplasia
UK RCPath	Royal College of Pathologists
VEGF	Vascular endothelial growth factor
WHO	World health organization
ZEB	Zinc-finger E-box-binding homeobox

LIST OF FIGURES

No.	Title	Page
1	Functional consequences of a type III epithelial-to-mesenchymal transition.	67
2	Signaling pathways regulating EMT.	71
3	Normal renal tissue positive for fibronectin (Control) (X 100).	129
4	Invasive duct carcinoma of no special type Grade II (H&E X 100).	129
5	Invasive duct carcinoma of no special type Grade II (H&E X 100).	130
6	Invasive duct carcinoma of no special type Grade II showing strong positive E-FN expression (X 200).	130
7	Invasive duct carcinoma of no special type Grade II showing Negative E-FN expression (X 200).	131
8	Intraduct carcinoma showing comedo (black arrow) and solid (blue arrow) types (H&E X 100 original magnification).	131
9	Intraduct carcinoma showing cribriform type (arrows) (H&E X 100 original magnification).	132
10	Intraduct carcinoma, comedo type showing strong Positive E-FN expression (X 40 original magnification).	132
11	Intraduct carcinoma, cribriform type, showing Negative E-FN expression (X 100 original magnification).	133
12	Invasive lobular carcinoma Grade II (H&E X 100 original magnification).	133
13	Invasive lobular carcinoma Grade II showing moderate Positive E-FN expression (X 200 original magnification).	134
14	Invasive lobular carcinoma Grade II showing Negative E-FN expression (X 200 original magnification).	134
15	Acini distended by cells having lobular neoplasia features in the form of LCIS with obliteration of the lumen (black arrows) and ALH with preserved lumen (blue arrows) (H&E X 100 original magnification).	135
16	Insitu lobular carcinoma showing moderate Positive E-FN expression (X 100 original magnification).	135
17	Mucinous carcinoma Grade II, arrows pointing to mucin lakes (H&E X 100 original magnification).	136
18	Mucinous carcinoma Grade II showing Negative E-FN expression (X 100 original magnification).	136

19	Invasive papillary carcinoma Grade II showing mainly solid type (arrows pointing to fibrovascular cores) (arrow) (H&E X 40 original magnification).	137
20	Invasive papillary carcinoma Grade II showing moderate Positive E-FN expression (X 100 original magnification).	137
21	Invasive micropapillary carcinoma Grade II (H&E X 100 original magnification).	138
22	Invasive micropapillary carcinoma Grade II showing Strong E-FN expression (X 100 original magnification).	138
23	Invasive mixed ductal and lobular carcinoma Grade II showing ductal component (Black arrow) and lobular component (Blue arrows) (H&E X 100 original magnification).	139
24	Invasive mixed ductal and lobular carcinoma Grade II with ductal component (Black arrow) and lobular component (red arrow) showing Negative E-FN expression (X 100 original magnification).	139
25	Invasive duct carcinoma Grade III showing marked nuclear anaplasia (Arrows) (H&E X 200 original magnification).	140
26	Invasive duct carcinoma Grade III showing strong positive E-FN expression (X 400 original magnification).	140
27	Strong S-FN expression in the form of coarse FN-positive strands (arrows) (X 100 original magnification).	141
28	Moderate S-FN expression in the form of fine FN-positive strands (X 100 original magnification).	141
29	Mild S-FN expression in the form of few scattered FN-positive strands (X 100 original magnification)	142
30	Negative S-FN expression (X 100 original magnification).	142
31	Case showing Positive LVI in the peritumoral area (H&E X 400 original magnification).	143
32	Case showing Positive LVI in the peritumoral area (H&E X 400 original magnification).	143
33	Intense peritumoral lymphocytic infiltrate (Arrows) (H&E X 100 original magnification).	143
34	Mild peritumoral lymphocytic infiltrate (Arrows) (H&E X 200 original magnification).	144
35	A case of stroma rich Invasive duct carcinoma (H&E X 40 Original magnification).	144
36	A case of stroma poor Invasive duct carcinoma (H&E X 100 original magnification).	145

LIST OF TABLES

No.	Title	Page
1	Features of molecular subtypes of breast cancer.	31
2	TNM staging system of the breast cancer.	51
3	Anatomic stage/prognostic groups of breast cancer.	53
4	Histologic grading of breast cancer.	56
5	Age in the studied cases.	87
6	Histologic types in the studied cases.	88
7	Prognostic groups/ anatomical stages in the studied cases.	90
8	Relation between age (in years) and the E-FN expression.	95
9	Relation between the histologic types and E-FN expression.	96
10	Relation between the histologic grade and E-FN expression.	97
11	Relation between the T stage and E-FN expression.	98
12	Relation between the N stage and E-FN expression.	99
13	Relation between the prognostic stages and E-FN expression.	100
14	Relation between the insitu component and E-FN expression.	101
15	Relation between ER status and E-FN expression.	102
16	Relation between PR status and E-FN expression.	103
17	Relation between HER2 over-expression and E-FN expression.	104
18	Relation between Ki-67 index and E-FN expression.	105
19	Relation between the breast cancer subtypes and E-FN expression.	106
20	Relation between multiplicity of masses and E-FN expression.	107
21	Relation between the presence of LVI and the E-FN expression.	108
22	Relation between extent of peri-tumoral lymphocytic infiltration and E-FN expression.	109
23	Relation between the amount of tumor associated stroma (desmoplasia) and E-FN expression.	110
24	Relation between age (in years) and S-FN expression.	112
25	Relation between Histologic subtypes and S-FN expression.	113
26	Relation between Histologic grade and S-FN expression.	114
27	Relation between the T stage and S-FN expression.	115
28	Relation between the N stage and S-FN expression.	116
29	Relation between the prognostic stages and S-FN expression.	117
30	Relation between the presence of insitu component and S-FN expression.	118
31	Relation between ER status and S-FN expression.	119
32	Relation between PR status and S-FN expression.	120
33	Relation between HER2 over-expression and S-FN expression.	121
34	Relation between Ki-67 index and S-FN expression.	122

35	Relation between the molecular subtypes and S-FN expression.	123
36	Relation between the multiplicity of masses and S-FN expression.	124
37	Relation between the presence of LVI and S-FN expression.	125
38	Relation between the extent of lymphocytic infiltration and S-FN expression.	126
39	Relation between desmoplasia and S-FN expression.	127
40	Relation between S-FN expression and E-FN expression	128

LIST OF GRAPHS

No.	Title	Page
1	Histologic types in the studied cases.	88
2	Histologic grade in the studied cases.	89
3	T stage in the studied cases.	89
4	N Stage in the studied cases.	90
5	Insitu component in the studied cases.	91
6	ER status in the studied cases.	91
7	PR status in the studied cases.	91
8	HER2 overexpression in the studied cases.	92
9	Ki-67 proliferation index in the studied cases.	92
10	Molecular subtypes of the studied cases.	92
11	Multiplicity of masses in the studied cases.	93
12	Lymphovascular invasion in the studied cases.	93
13	Extent of peri-tumoral lymphocytic infiltration in the studied cases.	94
14	Tumor associated stroma (desmoplasia) in the studied cases.	94
15	Epithelial fibronectin immunohistochemical expression in the studied cases.	95
16	Relation between the histologic types and E-FN expression.	96
17	Relation between the histologic grade and E-FN expression.	97
18	Relation between the T stage and E-FN expression.	98
19	Relation between the N stage and E-FN expression.	99
20	Relation between the prognostic stages and E-FN expression.	100
21	Relation between the insitu component and E-FN expression.	101
22	Relation between ER status and E-FN expression.	102
23	Relation between PR status and E-FN expression.	103
24	Relation between HER2 over-expression and E-FN expression.	104
25	Relation between Ki-67 index and E-FN expression.	105
26	Relation between the breast cancer subtypes and E-FN expression.	106
27	Relation between multiplicity of masses and E-FN expression.	107
28	Relation between the presence of LVI and the E-FN expression.	108

29	Relation between extent of peri-tumoral lymphocytic infiltration and E-FN expression.	109
30	Relation between the amount of tumor associated stroma (desmoplasia) and E-FN expression.	110
31	Stromal fibronectin immunohistochemical expression in the studied cases.	111
32	Relation between age (in years) and S-FN expression.	112
33	Relation between Histologic subtypes and S-FN expression.	113
34	Relation between Histologic grade and S-FN expression.	114
35	Relation between the T stage and S-FN expression.	115
36	Relation between the N stage and S-FN expression.	116
37	Relation between the prognostic stages and S-FN expression.	117
38	Relation between the presence of insitu component and S-FN expression.	118
39	Relation between ER status and S-FN expression.	119
40	Relation between PR status and S-FN expression.	120
41	Relation between HER2 over-expression and S-FN expression.	121
42	Relation between Ki-67 index and S-FN expression.	122
43	Relation between the multiplicity of masses and S-FN expression.	123
44	Relation between the presence of LVI and S-FN expression.	124
45	Relation between the extent of lymphocytic infiltration and S-FN expression.	125
46	Relation between desmoplasia and S-FN expression.	126
		127
47	Relation between S-FN expression and E-FN expression	128